Liver Resection for Neuroendocrine Tumors Liver Metastases in Transplantable Patients within the Milan Criteria Abstract #2274

Introduction: Liver transplantation (LT) has been prosed as a curative treatment for metastatic gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) but there is a lack of consensus on its real benefit when compared with hepatectomy.
Aim(s): We sought to analyze survival outcomes of patients undergoing liver resection for GEP-NETs liver metastasis (NELM) according to the Milan Criteria proposed to select patients with GEP-NET candidate to LT.
Materials and methods: A multicentric database including seven tertiary referral centers was used to identify patients submitted to hepatectomy for NELM between January 1990 and December 2014. We identify patients fulfilling Milan Criteria: well-differentiated NET (Ki-67<10%), age <60 years, no extrahepatic disease, primary NET resected, stable disease for >6 months, and <50% liver involvement (Group 1). Extended Milan Criteria included patients up to 70 years age old (Group 2). Recurrence after liver surgery was treated according to international guidelines. No patients underwent liver transplantation during the follow-up
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD, PhD Andrea Ruzzenente

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1261 Emergency Therapy for Liver Metastases from Advanced VIPoma: Surgery or Transarterial Chemoembolization
Introduction: VIPoma is a rare neuroendocrine tumor (NET) with a high potential to develop hepatic metastases and poor prognosis. The primitive tumor is non-symptomatic and usually localized within the pancreas. Liver metastasis drove the prognosis and induced profuse watery diarrhea or renal failure.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Johann Dréanic
#1348 Resectable Primary Tumor in Patients with Pancreatic Neuroendocrine Tumors Located to the Body or Tail and Unresectable Liver Metastases: Does Distal Pancreatectomy Improve Survival?
Introduction: The role of primary tumor surgery in pancreatic neuroendocrine tumor (PNET) with unresectable liver metastases is controversial and international guidelines do not recommend surgery in that setting of patients
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Dr Emilio Bertani
Authors: Bertani E, Fazio N, Grana C, Chiappa A, ...
#1481 Neuroendocrine Liver Metastasis: A Novel Nomogram to Predict Patient’s Prognosis After Liver Resection
Introduction: Despite surgery remains the only potentially curative option for patients with neuroendocrine liver metastases (NELMs), the factors determining the prognosis of patients following hepatectomy are poorly understood.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Fabio Bagante
#1604 Resection of Liver Metastases in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas: A Nordic Multicenter Study
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Currently, resection of liver metastases in patients with metastatic GEP-NEC is not recommended. However, the existing data are scarce.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: MD Renate Berget Galleberg
#3064 ALPPS for Neuroendocrine Liver Metastases Not Suitable for Conventional Hepatic Resection - Interim Analysis of the International ALPPS Registry
Introduction: Surgery is the most effective treatment option for neuroendocrine liver metastases (NELM). However, the majority of patients with NELM do not have disease that is resectable using conventional methods. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a relatively novel two-stage strategy in hepatic surgery.
Conference: 17th Annual ENETS Conference (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Ashley Clift
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team